{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:06:42Z","timestamp":1790114802357,"version":"4.0.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.fjurol.2026.103105","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:26:00Z","timestamp":1776295560000},"page":"103105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG"],"prefix":"10.1016","volume":"36","author":[{"given":"Priscilla","family":"Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I.","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Long Depaquit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Constance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2026.103105_bib0460","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.fjurol.2024.102742","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0update 2024\u20132026: non-muscle invasive bladder cancer (NMIBC)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0465","doi-asserted-by":"crossref","first-page":"103011","DOI":"10.1016\/j.fjurol.2025.103011","article-title":"French recommendations of the AFU Oncology Committee for Bladder Cancer: update 2025","volume":"35","author":"Roumigui\u00e9","year":"2025","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0470","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0475","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2026.103105_bib0485","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0003-4401(01)00085-7","volume":"36","author":"Saint","year":"2002","journal-title":"Ann Urol (Paris)"},{"key":"10.1016\/j.fjurol.2026.103105_bib0490","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0495","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0500","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly Bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO Study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0505","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"P\u00e9rez-Jacoiste As\u00edn","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.fjurol.2026.103105_bib0510","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.medmal.2018.11.014","article-title":"Bacillus Calmette-Guerin infection following intravesical instillation: does the strain matter?","volume":"49","author":"Levi","year":"2019","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.fjurol.2026.103105_bib0515","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.rmr.2017.11.010","article-title":"BCGites apr\u00e8s immunoth\u00e9rapie pour cancer de vessie, une pathologie h\u00e9t\u00e9rog\u00e8ne\u00a0: physiopathologie, description clinique, prise en charge diagnostique et th\u00e9rapeutique [BCG infection following intravesicular immunotherapy for bladder cancer]","volume":"35","author":"Levi","year":"2018","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.fjurol.2026.103105_bib0520","first-page":"763","article-title":"Pulmonary complications of intravesical Bacille Calmette-Gu\u00e9rin immunotherapy","volume":"135","author":"Israel-Biet","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.fjurol.2026.103105_bib0525","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0022-5347(17)37369-X","article-title":"Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity","volume":"147","author":"DeHaven","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0530","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/23744235.2015.1055794","article-title":"Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients","volume":"47","author":"Pommier","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.fjurol.2026.103105_bib0535","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.diagmicrobio.2016.04.006","article-title":"Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital","volume":"85","author":"Gonz\u00e1lez-Del Vecchio","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.fjurol.2026.103105_bib0540","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.purol.2012.04.019","volume":"22","author":"Neuzillet","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0545","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.purol.2022.01.001","volume":"32","author":"Audenet","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0550","series-title":"Survival of people with cancer in metropolitan France 1989\u20132018\u00a0\u2013\u00a0bladder","author":"Francim Network","year":"2021"},{"key":"10.1016\/j.fjurol.2026.103105_bib0555","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1002\/cam4.4219","article-title":"Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: a SEER database analysis with 19,919 patients","volume":"10","author":"Zhan","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.fjurol.2026.103105_bib0560","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0565","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0570","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0575","series-title":"Non-muscle-invasive Bladder Cancer EAU Guidelines [Internet]","author":"Gontero","year":"2025"},{"key":"10.1016\/j.fjurol.2026.103105_bib0580","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0585","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103105_bib0590","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.11.007","article-title":"Quinolone prophylaxis in conjunction with Bacillus Calmette-Gu\u00e9rin instillations for bladder cancer: time to reconsider the evidence and open the quinolone box?","volume":"10","author":"Liedberg","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2026.103105_bib0595","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus Calmette-Gu\u00e9rin treatment for bladder cancer: results of a randomized,prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2026.103105_bib0600","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0605","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/iju.14139","article-title":"Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Gu\u00e9rin?","volume":"27","author":"Herr","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0610","doi-asserted-by":"crossref","first-page":"1240378","DOI":"10.3389\/fonc.2023.1240378","article-title":"Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment","volume":"13","author":"Aubert","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0615","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. EMA\/175398\/2019, decision applicable 11 March 2019."},{"key":"10.1016\/j.fjurol.2026.103105_bib0620","series-title":"Nation-wide contemporary evaluation of BCG treatment adequacy in patients with non-muscle invasive bladder cancer and associated oncological outcomes. National communication AFU\/CFU","author":"Pattou","year":"2025"},{"key":"10.1016\/j.fjurol.2026.103105_bib0625","series-title":"Place of urine culture (ECBU) before interventional or surgical urological procedures in adults and management in case of colonization: scientific report","year":"2026"},{"key":"10.1016\/j.fjurol.2026.103105_bib0630","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0635","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-5347(01)65185-1","article-title":"Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer","volume":"157","author":"Zlotta","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0640","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/2326-6066.CIR-20-0638","article-title":"Therapy of established tumors with rationally designed multiple agents targeting diverse immune-tumor interactions: engage, expand, enable","volume":"9","author":"Fabian","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.fjurol.2026.103105_bib0645","doi-asserted-by":"crossref","first-page":"e001691","DOI":"10.1136\/jitc-2020-001691","article-title":"Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve","volume":"9","author":"Fabian","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.fjurol.2026.103105_bib0650","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","article-title":"Role of a bacillus Calmette-Gu\u00e9rin fibronectin attachment protein in BCG-induced antitumor activity","volume":"86","author":"Zhao","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.fjurol.2026.103105_bib0655","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1128\/iai.56.12.3046-3051.1988","article-title":"Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG","volume":"56","author":"Abou-Zeid","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.fjurol.2026.103105_bib0660","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Gu\u00e9rin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0665","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1464-410X.1995.tb07309.x","article-title":"The persistence of bacille Calmette-Gu\u00e9rin in the bladder after intravesical treatment for bladder cancer","volume":"75","author":"Bowyer","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0670","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1128\/JCM.01595-10","article-title":"Detection of Bacillus Galmette-Gu\u00e9rin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma","volume":"49","author":"Siatelis","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0675","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0022-5347(05)66410-5","article-title":"The fate of bacillus Calmette-Gu\u00e9rin after intravesical instillation","volume":"165","author":"Durek","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0680","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/S0022-5347(01)68169-2","article-title":"Detection of bacillus Calmette-Gu\u00e9rin in the blood by the polymerase chain reaction method of treated bladder cancer patients","volume":"158","author":"Tuncer","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0685","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103105_bib0690","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0695","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CAD.0000000000000456","article-title":"Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer","volume":"28","author":"Nouhaud","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.fjurol.2026.103105_bib0700","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Gu\u00e9rin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0705","first-page":"542","article-title":"[Intravesical BCG-therapy: comparison of side effects of Connaught (Toronto) and Pasteur (Paris) strains]","volume":"10","author":"Champetier","year":"2000","journal-title":"Prog Urol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.fjurol.2026.103105_bib0710","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: a solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0715","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0720","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Gu\u00e9rin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103105_bib0725","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-5347(17)45606-0","article-title":"Complications of bacillus Calmette-Gu\u00e9rin immunotherapy in 1278 patients with bladder cancer","volume":"135","author":"Lamm","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0730","first-page":"604","article-title":"[Surveillance of the safety of intravesical BCG therapy in France: quantitative analysis of serious adverse events notified over a period of five years]","volume":"12","author":"Debois","year":"2002","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0735","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7863\/jum.2007.26.5.671","article-title":"Tuberculous epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma: sonographic findings","volume":"26","author":"Salvador","year":"2007","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.fjurol.2026.103105_bib0740","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/ijr.14.41","article-title":"Reactive arthritis following Bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"9","author":"Cardozo","year":"2014","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0745","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-5347(17)37354-8","article-title":"Hypersensitivity systemic reaction following intravesical bacillus Calmette-Gu\u00e9rin: successful treatment with steroids","volume":"147","author":"Molina","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0750","first-page":"5548054","article-title":"Effectiveness of steroid pulse therapy for systemic side effects after Bacillus Calmette-Gu\u00e9rin intravesical instillation therapy: a series of five cases","volume":"2021","author":"Umemoto","year":"2021","journal-title":"Case Rep Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0755","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-5347(17)39752-5","article-title":"Clinical and pathological findings in prostates following intravesical bacillus Calmette-Gu\u00e9rin instillations","volume":"144","author":"Mukamel","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0760","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0765","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2026.103105_bib0770","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0775","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.fjurol.2026.103105_bib0780","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2026.103105_bib0785","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0790","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, BCG-MEDAC, poudre et solvant pour suspension intrav\u00e9sicale. Base de donn\u00e9es publique des m\u00e9dicaments. Available at: https:\/\/base-donee-publique.medicaments.gouvr.fr\/medicament\/60973899\/extrait (Accessed March 6, 2026)."},{"key":"10.1016\/j.fjurol.2026.103105_bib0795","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-020-00642-1","article-title":"Can we treat bladder cancer with intravesical Bacillus Calmette-Gu\u00e9rin in patients with prior tuberculosis infection? A population-based cohort study","volume":"8","author":"Hsu","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0800","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer--a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0805","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-005-0059-2","article-title":"Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review","volume":"26","author":"Tinazzi","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.fjurol.2026.103105_bib0810","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00042737-200410000-00012","article-title":"Bacillus Calmette-Gu\u00e9rin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma","volume":"16","author":"Van Outryve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0815","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.fjurol.2026.103105_bib0820","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.5489\/cuaj.1411","article-title":"Complications of intravesical Bacillus Calmette-Gu\u00e9rin","volume":"8","author":"Macleod","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.fjurol.2026.103105_bib0825","doi-asserted-by":"crossref","first-page":"6230409","DOI":"10.1155\/2019\/6230409","article-title":"Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Gu\u00e9rin for bladder cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0830","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u00a0\u2013\u00a02019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0835","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0840","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.juro.2012.10.070","article-title":"Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Gu\u00e9rin treatment","volume":"189","author":"Johnson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0845","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.urolonc.2020.11.037","article-title":"BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review","volume":"39","author":"Cabas","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0850","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2466-14-35","article-title":"BCG-induced pneumonitis with lymphocytic pleurisy in the absence of elevated KL-6","volume":"14","author":"Tobiume","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.fjurol.2026.103105_bib0855","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.autrev.2013.06.017","article-title":"Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature","volume":"12","author":"Bernini","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.fjurol.2026.103105_bib0860","doi-asserted-by":"crossref","first-page":"e249208","DOI":"10.1136\/bcr-2022-249208","article-title":"Reactive arthritis following treatment with intravesical Bacillus Calmette-Gu\u00e9rin for papillary carcinoma of bladder","volume":"15","author":"Singh","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.fjurol.2026.103105_bib0865","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2004.07.027","article-title":"Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Gu\u00e9rin therapy for superficial bladder carcinoma","volume":"65","author":"Falkensammer","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2026.103105_bib0870","doi-asserted-by":"crossref","first-page":"354","DOI":"10.14740\/jmc4323","article-title":"Epididymo-orchitis mimicking malignancy resulting from intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: an attempt to understand pathophysiology, diagnostic challenges, patients\u2019 implications and future directions","volume":"15","author":"Prasad","year":"2024","journal-title":"J Med Cases"},{"key":"10.1016\/j.fjurol.2026.103105_bib0875","first-page":"1554","article-title":"Investigation of granulomatous prostatitis incidence following intravesical BCG therapy","volume":"7","author":"Balasar","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.fjurol.2026.103105_bib0880","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.12998\/wjcc.v11.i9.2051","article-title":"Granulomatous prostatitis after bacille Calmette-Gu\u00e9rin instillation resembles prostate carcinoma: a case report and review of the literature","volume":"11","author":"Yao","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.fjurol.2026.103105_bib0885","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0022-5347(05)67025-5","article-title":"Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Gu\u00e9rin","volume":"164","author":"Leibovici","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0890","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11604-025-01871-w","article-title":"MRI findings of granulomatous prostatitis induced by intravesical Bacillus Calmette-Gu\u00e9rin treatment for bladder cancer: a comparison with prostate cancer","volume":"44","author":"Ito","year":"2026","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0895","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13256-023-04310-4","article-title":"Granulomatous myocarditis arising from intravesical Bacillus Calmette-Gu\u00e9rin therapy leading to death diagnosed by postmortem examination: a case report","volume":"18","author":"Geetha","year":"2024","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.fjurol.2026.103105_bib0900","first-page":"101655","article-title":"Miliary tuberculosis following intravesical Bacillus Calmette and Gu\u00e9rin therapy: a rare complication of a frequent procedure","volume":"38","author":"Loued","year":"2021","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.fjurol.2026.103105_bib0905","doi-asserted-by":"crossref","first-page":"4574879","DOI":"10.1155\/2021\/4574879","article-title":"Acute hepatitis induced by intravesical bcg therapy: a rare but serious complication","volume":"2021","author":"Abid","year":"2021","journal-title":"Case Reports Hepatol"},{"key":"10.1016\/j.fjurol.2026.103105_bib0910","first-page":"101902","article-title":"A case of disseminated M. bovis bacillus Calmette-Gu\u00e9rin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017\u20132022","volume":"45","author":"Nishimura","year":"2023","journal-title":"Respir Med Case Rep"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:35:35Z","timestamp":1790112935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950393026000367"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103105","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103105"}}